About this episode

The episode discusses limited therapeutic options for metastatic colorectal cancer and explores newer treatments like trifluridine-tipiracil and fruquitinib.

Good therapeutic options for metastatic colorectal cancer are limited after the fluoropyrimidine-based options are exhausted. This week, we explore the role of trifluridine-tipiracil (Lonsurf) and bevacizumab (VEGF inhibitor), and a newish kid on the block, fruquitinib, an oral tyrosine kinase inhibitor and vascular endothelial growth factor receptor. While not perfect, they do represent later-line options for patients Studies discussed in this episode: SUNLIGHT FRESCO-2 For more episodes, resources and blog posts, visit www.inquisitiveonc.com Please find us on Twitter @InquisitiveOnc! If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com Art courtesy of Taryn Silver Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/ Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more…

People in this episode

Hosts: Michael Fernando, Josh Hurwitz

Topics covered

• metastatic colorectal cancer
• therapeutic options
• trifluridine-tipiracil
• bevacizumab
• fruquitinib
• VEGF inhibitor
• oral tyrosine kinase inhibitor

Keywords

• metastatic colorectal cancer
• trifluridine-tipiracil
• Lonsurf
• bevacizumab
• fruquitinib
• VEGF inhibitor
• oral tyrosine kinase inhibitor
• SUNLIGHT FRESCO-2

Sponsors

Pfizer, Merck Pharmaceuticals

Mentioned in this episode

Products: trifluridine-tipiracil, Lonsurf, bevacizumab, fruquitinib

Explore listener stats, chart rankings, contacts and more on the Oncology for the Inquisitive Mind podcast page.